Clinical experience with Escherichia coli rHuGM-CSF.
The use of rHuGM-CSF has resulted in patient benefit as shown by reduced infections (MDS and AA), reduced days in intensive care (ABM transplant), better adherence to cancer chemotherapy protocols, and the ability to use full doses of antiviral drugs in AIDS and cytomegalovirus retinitis. The adverse reactions are significant when high doses are used, therefore high doses should be avoided (there is a plateau in the dose-effective biological responses). At recommended doses, GM-CSF is well tolerated and is a valuable adjunctive therapy in the management of patients with conditions of dysmyelopoiesis and myeloid hypoplasia associated with myelotoxic therapy, or after bone marrow transplantation.
Stern
A C
AC
Sandoz Pharma Ltd., Basel, Switzerland.
Jones
T C
TC
D000970:Antineoplastic Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D004926:Escherichia coli / Q000235:genetics*; D006085:Graft Survival / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation / Q000139:chemically induced; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*; D011182:Postoperative Care; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007155:Immunologic Factors; D011993:Recombinant Fusion Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor